Key Segments:
By Product Type
-
Handheld/Spot-Check Devices
-
Continuous Monitoring Devices
-
Wearable Devices
-
Sensors & Accessories
By Technology
-
Pulse CO-Oximetry/Optical Sensing
-
Computer Vision & AI-Based Estimation
-
Others
By End User
-
Hospitals & Clinics
-
Ambulatory Surgical Centers
-
Diagnostic Laboratories & Blood Banks
-
Home Healthcare
-
Research & Academic Institutions
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company's specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product Type X End User)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The market includes Masimo Corporation, now a standalone business unit of Danaher Corporation, OrSense Ltd., EzeRx, GE HealthCare Technologies, Siemens Healthineers AG, Medtronic plc, Nihon Kohden Corporation, Sysmex Corporation and Robert Bosch GmbH, among others. These providers compete on sensing accuracy, clinical validation depth, blood-bank donor-screening partnerships and integration with existing patient monitoring platforms.
The main opportunities lie in smartphone- and AI-based hemoglobin estimation that needs no dedicated sensor hardware, and in expanding into large public anemia-screening programs across South Asia and Sub-Saharan Africa that need low-cost point-of-care alternatives to laboratory testing.
The key growth factor is rising demand for needle-free point-of-care hemoglobin screening at blood donation centers, combined with hospital patient blood management programs that are adding continuous noninvasive hemoglobin monitoring to perioperative care.
By product type, the Handheld/Spot-Check Devices segment dominated the market with approximately 41.20% share in 2025, supported by its low cost and use across high-volume donor and outpatient screening. The Pulse CO-Oximetry/Optical Sensing technology and Hospitals & Clinics end-user segment led their respective axes.
North America dominated the market with approximately 42.35% share in 2025, supported by widespread blood-center donor-screening conversion and hospital patient blood management adoption. Asia Pacific is the fastest-growing region, driven by large national anemia-screening programs.
